Best Peptides for Immune Support

Evidence level: Peer reviewed (clinical trials + international approvals, no FDA approval)

Regulatory status: Not FDA-approved — approved in 30+ countries; FDA Fast Track designation for select oncology indications

Thymosin Alpha-1 (Tα1) is a naturally occurring thymic peptide that modulates immune function by enhancing T-cell maturation, dendritic cell activity, and cytokine production. It is marketed as Zadaxin (SciClone Pharmaceuticals) and is approved in over 30 countries for chronic hepatitis B, hepatitis C, and as an immune adjuvant, but has never received FDA approval in the United States. The compound received FDA Fast Track designation for certain oncology indications. Over 100 clinical trials have been registered on ClinicalTrials.gov studying thymosin alpha-1 across infectious disease, oncology, and immune support contexts. During the COVID-19 pandemic, thymosin alpha-1 was investigated as an immune modulator in severe cases; retrospective data suggested potential mortality benefit in critically ill patients, but randomized controlled trial evidence remains limited. King & Tuthill (2016) published a comprehensive review of immune modulation with thymosin alpha-1 in Expert Review of Clinical Immunology, summarizing its mechanism and clinical development history.

Evidence level: Peer reviewed (preclinical / in vitro, no clinical approval)

Regulatory status: Not FDA-approved — no approved therapeutic products; FDA bulk risk list applies

LL-37 is the only human member of the cathelicidin family of antimicrobial peptides (AMPs), encoded by the CAMP gene. It plays a key role in innate immunity through direct antimicrobial activity against bacteria, viruses, and fungi, and also modulates immune signaling and wound healing. Dürr et al. (2006) published a foundational review in Biochimica et Biophysica Acta describing LL-37's structure, mechanism, and biological roles as the only human cathelicidin. Kahlenberg & Kaplan (2013) reviewed LL-37's dual role in innate immunity and autoimmunity in the Journal of Immunology, noting both protective antimicrobial effects and pro-inflammatory potential in autoimmune disease. LL-37 is not FDA-approved for any indication and no approved therapeutic products containing LL-37 are marketed in the United States. ClinicalTrials.gov lists limited interventional studies. The biohacking community has adopted LL-37 for self-directed immune support and wound healing, despite the absence of clinical trial data supporting its safety or efficacy in these contexts.

Evidence level: Preclinical (animal models only, no human trials)

Regulatory status: Not FDA-approved — investigational; scheduled for FDA advisory committee discussion July 2026

KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone). Preclinical studies report that KPV has anti-inflammatory effects in animal models, but no human clinical trials have been published. The evidence base is entirely preclinical. KPV is not FDA-approved for any indication and is scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting. The peptide is discussed online as an oral anti-inflammatory and immune-support compound despite the lack of human clinical evidence. The FDA has identified certain bulk peptide substances as potentially presenting significant safety risks in compounding contexts.